Research Information System
Nuclear medicine communications, vol.38, no.1, pp.76-83, 2017 (SCI-Expanded)
ObjectiveIn this observational pilot study, we aimed to evaluate the role of gallium-68-labelled DOTA-TATE (Ga-68-TATE) PET/computed tomography (CT) scanning in patients with multiple myeloma (MM), considering previous promising results obtained from conventional somatostatin receptor scintigraphy with In-111 pentetreotide.Materials and methodsTwenty-one patients with a diagnosis of MM were prospectively included in this study: eight patients were referred for initial staging and 13 patients for restaging purpose. Both fluorine-18 fluorodeoxyglucose (F-18-FDG) and TATE PET/CT scanning were performed in all patients.ResultsAll patients had one or more PET-positive lesion on either F-18-FDG or TATE scans. Six patients had an additional diffusely increased bone marrow activity on F-18-FDG scans, five of whom also had a concordant bone marrow appearance on TATE scans. Each PET set (either F-18-FDG or TATE) was positive in 19 patients. There was a discordant result in four (19%) patients between F-18-FDG and TATE scans. F-18-FDG scans showed 112 lesions (86 TATE-positive; 26 TATE-negative) in 19 patients, whereas TATE scans showed 108 lesions (86 F-18-FDG-positive; 22 F-18-FDG-negative) in 19 patients. No significant difference was found between the two modalities in terms of lesion numbers detected (P=0.67). However, the presence of diffuse bone marrow uptake of TATE seems to be a predicting factor for the overall survival (P=0.033, hazard ratio: 15.2 and 95% confidence interval: 1.2-185.5).ConclusionTATE PET/CT seems to be an alternative imaging modality and may play a complementary role in MM management, at least by providing a different pathobiological insight into the disease.